Columbia Laboratories Advances Clinical Development of Lidocaine Candidate.
Business Wire › November 07, 2006
Linked as:
Extract
Columbia Laboratories Advances Clinical Development of Lidocaine Candidate.
Vaginally-Administered Lidocaine under Development to Prevent and Treat Dysmenorrhea
LIVINGSTON, N.J. -- Columbia Laboratories (NASDAQ: CBRX) initiated a 42-patient clinical study of its vaginally-administered lidocaine candidate, which the Company is developing to prevent and treat dysmenorrhea....See the full content of this document
Sponsored links
